{"id":952558,"date":"2026-04-17T11:17:06","date_gmt":"2026-04-17T15:17:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/"},"modified":"2026-04-17T11:17:06","modified_gmt":"2026-04-17T15:17:06","slug":"psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/","title":{"rendered":"Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine"},"content":{"rendered":"

\nCompany highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply
\n<\/h2>\n
\n

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (\u201cPsyence BioMed\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies, today acknowledged recent reports that the U.S. administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder (PTSD), addiction, and other serious neurological and mental health conditions.<\/p>\n

The anticipated executive action reflects growing recognition of the need for rigorous, regulated research into novel therapies, particularly in areas where current treatment options remain limited.<\/p>\n

\u201cIbogaine has emerged as a compound of increasing global interest, particularly for its potential to address complex and treatment-resistant conditions,\u201d said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. \u201cWe welcome efforts to advance structured, evidence-based research that can more clearly define its safety, efficacy, and role in clinical care.\u201d<\/p>\n

Ibogaine remains a Schedule I substance in the United States, and patients often seek access through unregulated settings outside the country. Psyence BioMed believes that advancing controlled clinical research and regulated development pathways is essential to improving both patient safety and long-term access.<\/p>\n

\n Global Leadership in GMP Manufacturing and Ethical Sourcing<\/strong>\n <\/p>\n

Through its strategic investment in PsyLabs, Psyence BioMed has established a leading position in the GMP-compliant manufacturing of ibogaine and ibogaine derivatives, with operations aligned to support global clinical research and future therapeutic development.\u00a0The Company has also previously announced the development of a responsible and ethically sourced ibogaine supply chain, working within the compound\u2019s native African ecosystem to ensure sustainability, traceability, and respect for traditional and environmental considerations.<\/p>\n

As global interest in ibogaine accelerates, Psyence BioMed\u2019s integrated platform \u2013 combining ethical sourcing, GMP manufacturing, and clinical development capabilities \u2013 positions the Company to play a meaningful role in supporting the next phase of research and potential regulatory evolution.<\/p>\n

\u201cOur focus has been on building a high-quality, ethically grounded supply chain that can support clinical research at scale,\u201d added Aufrichtig. \u201cAs the regulatory environment evolves, the availability of standardized, responsibly sourced ibogaine will be critical to enabling credible scientific progress.\u201d<\/p>\n

\n About\u00a0Psyence\u00a0BioMed<\/strong>\u00a0<\/p>\n

Psyence\u00a0Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.\u00a0<\/p>\n

\n About PsyLabs<\/strong>\n <\/p>\n

PsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner.<\/p>\n

PsyLabs operates from an ISO 22000 and GMP compliant facility, ensuring the highest standards of safety and traceability. With a focus on natural compound purification, regulatory support, and global distribution, PsyLabs is expanding its product pipeline to include ibogaine and other next-generation psychedelics.
www.psylabs.life<\/a><\/p>\n

Learn more at www.psyencebiomed.com<\/u><\/a> and on LinkedIn.<\/u><\/a><\/p>\n

\n Contact Information for Psyence Biomedical Ltd.<\/strong>
\n
Email: ir@psyencebiomed.com<\/a>\u00a0\u00a0
Media Inquiries: media@psyencebiomed.com<\/a>
General Information: info@psyencebiomed.com<\/a>
Phone: +1 416-477-1708<\/p>\n

\n Investor Contact:<\/strong>
\n
Michael Kydd
Investor Relations Advisor
michael@psyencebiomed.com<\/a><\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

This communication contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as \u201cwill likely result,\u201d \u201care expected to,\u201d \u201cwill continue,\u201d \u201cis anticipated,\u201d \u201cestimated,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cprojection,\u201d \u201coutlook\u201d or words of similar meaning.<\/p>\n

Forward-looking statements in this communication include statements regarding the progress of the Phase IIb clinical trial, and trial execution under the newly engaged CRO, and the creation of long-term shareholder value. These forward-looking statements are based on a number of assumptions, including the assumption that there will be no delays in the execution of the Phase IIb clinical trial implementation schedule, topline data from this trial will be positive, and that the demand for psychedelic-assisted therapy will continue to increase and that the Company will be able to maintain a share price trading above $1.00 per share. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.<\/p>\n

These risks and uncertainties include, among others: (i) delays in the execution of the Phase IIb trial; (ii) the Company\u2019s ability to maintain compliance with Nasdaq\u2019s continued listing standards; (iii) volatility in the market price of the Company\u2019s common stock due to a variety of factors, including the Company\u2019s recent share consolidation, changes in market, economic or industry conditions in which Psyence BioMed operates and variations in performance across competitors, and (iv) changes in laws and regulations affecting Psyence BioMed\u2019s business and changes in Psyence BioMed\u2019s capital structure. Additionally, there can be no assurance that the anticipated executive order will be issued, or, if issued, that it will have any particular scope, timing or effect on the Company, its operations, product candidates or applicable regulatory pathways. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the \u201cRisk Factors\u201d section of the Company\u2019s final prospectus (File No. 333-284444) filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on January 24, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.<\/p>\n

These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.<\/p>\n

The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, ibogaine, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, ibogaine, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company\u2019s performance and operations.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (\u201cPsyence BioMed\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies, today acknowledged recent reports that the U.S. administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder (PTSD), addiction, and other serious neurological and mental health conditions. The anticipated executive action reflects growing recognition of the need for rigorous, regulated research into novel therapies, particularly in areas where current treatment options remain limited. \u201cIbogaine has emerged as a … <\/p>\n

Continue reading “Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952558","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPsyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (\u201cPsyence BioMed\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies, today acknowledged recent reports that the U.S. administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder (PTSD), addiction, and other serious neurological and mental health conditions. The anticipated executive action reflects growing recognition of the need for rigorous, regulated research into novel therapies, particularly in areas where current treatment options remain limited. \u201cIbogaine has emerged as a … Continue reading "Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T15:17:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTk4MSM3NTQxNDMwIzIyODU5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine\",\"datePublished\":\"2026-04-17T15:17:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\\\/\"},\"wordCount\":1274,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTk4MSM3NTQxNDMwIzIyODU5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\\\/\",\"name\":\"Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTk4MSM3NTQxNDMwIzIyODU5MTc=\",\"datePublished\":\"2026-04-17T15:17:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTk4MSM3NTQxNDMwIzIyODU5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTk4MSM3NTQxNDMwIzIyODU5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/","og_locale":"en_US","og_type":"article","og_title":"Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine - Market Newsdesk","og_description":"Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (\u201cPsyence BioMed\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies, today acknowledged recent reports that the U.S. administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder (PTSD), addiction, and other serious neurological and mental health conditions. The anticipated executive action reflects growing recognition of the need for rigorous, regulated research into novel therapies, particularly in areas where current treatment options remain limited. \u201cIbogaine has emerged as a … Continue reading \"Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-17T15:17:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTk4MSM3NTQxNDMwIzIyODU5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine","datePublished":"2026-04-17T15:17:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/"},"wordCount":1274,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTk4MSM3NTQxNDMwIzIyODU5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/","name":"Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTk4MSM3NTQxNDMwIzIyODU5MTc=","datePublished":"2026-04-17T15:17:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTk4MSM3NTQxNDMwIzIyODU5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTk4MSM3NTQxNDMwIzIyODU5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/psyence-biomed-welcomes-u-s-executive-action-to-advance-research-into-ibogaine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952558"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952558\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}